Article
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
Journal of clinical psychopharmacology - 1 Apr 2006
Hedenmalm Karin, Güzey Cüneyt, Dahl Marja-Liisa, Yue Qun-Ying, Spigset Olav
Abstract excerpt
INTRODUCTION: Extrapyramidal symptoms (EPS) are rare adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs). This study aimed to investigate the potential risk factors for EPS associated with SSRIs including polymorphisms of cytochrome P-450 isoenzymes, and serotonin and dopamine transporters and receptors. METHODS: All spontaneous adverse drug reaction reports received by the Swedish Medical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
